Clinical Focus


  • Nephrology

Academic Appointments


Professional Education


  • Board Certification: American Board of Internal Medicine, Nephrology (2015)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2015)
  • Fellowship: Columbia University Medical Center (2002) NY
  • Residency: New York University Medical Center (2000) NY
  • Internship: New York University Medical Center (1998) NY
  • Medical Education: Columbia University College of Physicians and Surgeons (1997) NY

2021-22 Courses


All Publications


  • Hypothesis: Accessory renal arteries may be an overlooked cause of renin-dependent hypertension. Journal of human hypertension Funes Hernandez, M., Bhalla, V., Isom, R. T. 2021

    View details for DOI 10.1038/s41371-021-00632-2

    View details for PubMedID 34785773

  • SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: A Case Report. Kidney medicine Wang, K. M., Isom, R. T. 2020; 2 (2): 218–21

    Abstract

    Euglycemic diabetic ketoacidosis is a rare but serious adverse effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors. We present a case of a woman in her 40s with type 2 diabetes mellitus hospitalized for revascularization for moyamoya disease who developed empagliflozin-associated euglycemic diabetic ketoacidosis despite having stopped the medication before admission. Surgical stress, acute postoperative illness, and decreased carbohydrate intake are postulated to be contributing factors to the development of ketosis in this patient, while near-normal glucose levels initially suggested nondiabetic ketoacidosis physiology and led to delayed diagnosis and treatment. Patients with type 2 diabetes mellitus may develop diabetic ketoacidosis during states of relative insulinopenia, most frequently from inadequate medication or intercurrent illness. During periods of carbohydrate deficiency, volume depletion, and upregulation of counter-regulatory stress hormones, SGLT2 inhibitor therapy can promote lipolysis and ketogenesis while maintaining euglycemia. Clinical considerations to ensure safe SGLT2 inhibitor therapy include appropriate holding parameters, timely diagnosis of euglycemic diabetic ketoacidosis, and recognition that the pharmacologic effects of SGLT2 inhibitor treatment may persist beyond several half-lives of elimination.

    View details for DOI 10.1016/j.xkme.2019.12.006

    View details for PubMedID 32734242

    View details for PubMedCentralID PMC7380362

  • Preparing for Hemodialysis CHRONIC RENAL DISEASE, 2ND EDITION Isom, R. T., Chertow, G. M., Kimmel, P. L., Rosenberg, M. E. 2020: 1157–73
  • Abatacept in Steroid-Dependent Minimal Change Disease and CD80-uria. Kidney international reports Isom, R., Shoor, S., Higgins, J., Cara-Fuentes, G., Johnson, R. J. 2019; 4 (9): 1349–53

    View details for DOI 10.1016/j.ekir.2019.05.1155

    View details for PubMedID 31517155

  • EUGLYCEMIC KETOACIDOSIS IN A POST-OPERATIVE PATIENT TAKING EMPAGLIFLOZIN Wang, K. M., Isom, R. T. W B SAUNDERS CO-ELSEVIER INC. 2019: 745
  • A Novel High-Resolution Magnetic Resonance Imaging Protocol Detects Aldosterone-Producing Adenomas in Patients with Negative Computed Tomography. American journal of hypertension Raber, I. n., Isom, R. T., Louie, J. D., Vasanawala, S. n., Bhalla, V. n. 2018

    View details for PubMedID 29648568

  • Planning for Hemodialysis CHRONIC RENAL DISEASE Isom, R. T., Chertow, G. M., Kimmel, P. L., Rosenberg, M. E. 2015: 751–64
  • Racial/Ethnic Disparities in Simultaneous Liver Kidney Transplantation: An Analysis from the UNOS Database Perumpail, R. B., Wong, R., Su, A. M., Isom, R., Scandling, J., Ahmed, A. WILEY-BLACKWELL. 2014: 472A–473A